We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Higher Tenascin-C Levels Associated with Cardiovascular Disease

By LabMedica International staff writers
Posted on 26 Mar 2020
Print article
Image: A solid phase sandwich ELISA for the determination of Tenascin-C; higher levels are Associated with Cardiovascular Disease (Immuno-Biological Laboratories, Inc).
Image: A solid phase sandwich ELISA for the determination of Tenascin-C; higher levels are Associated with Cardiovascular Disease (Immuno-Biological Laboratories, Inc).
Although there are several known biomarkers for cardiovascular (CV) risk that have been proposed to improve risk stratification in diabetes, they have not been incorporated into international guidelines.

Studies have shown that the extracellular matrix glycoprotein tenascin-C (TN-C) is transiently upregulated at sites of inflammation (e.g., after acute myocardial infarction), and as such, it is generally considered a marker of inflammation in CV diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, which is a condition associated with chronic low-grade inflammation and increased CV disease risk.

Scientists at the ELSAN, Polyclinique de Poitiers (Poitiers, France) and their many colleagues used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. They used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors.

The average age of the included individuals was 64 ± 11 years. Patients with a baseline estimated glomerular filtration rate <30 mL/min/1.73 m2, a history of prior renal replacement therapy, or a follow-up duration of <3 months were excluded. Blood samples and second morning urine samples were obtained from individuals after an overnight fast to measure various biological characteristics, such as hemoglobin A1c, low-density lipoprotein cholesterol, serum creatinine, and TN-C levels.

The team reported that higher TN-C concentrations were significantly associated with older age, longer duration of diabetes, history of CV disease, and diabetic retinopathy severity. Median follow-up duration was 89 months (range, 57-130 months), corresponding to 9,965 person-years. The overall mortality rate was 4.4% of total person-years of follow-up duration and the MACE rate was 5.2% of total person-years. The most common cause of death was CV diseases (54%). Baseline serum TN-C concentrations were higher in the group of individuals who died compared with survivors (89.3 ± 49.8 versus 69.0 ± 38.1 ng/mL) and higher in individuals with versus without incidental MACE (87.2 ± 48.4 versus 68.9 ± 38.6 ng/mL).

This study showed that higher serum TN-C concentrations were significantly associated with an increased risk for mortality and MACE in type 2 diabetes, even after adjustment for inflammatory markers such as angiopoietin-like 2 and tumor necrosis factor receptor 1 (TNFR1). The authors concluded that TN-C showed a significant predictive value not only for all-cause death, but also for MACE, suggesting that TN-C overexpression in individuals with type 2 diabetes may be linked to CV disease development and progression. The study was published ahead of print on February 10, 2020 in the journal Diabetologia.

Related Links:
ELSAN, Polyclinique de Poitiers

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.